Last week, biotech Cassava Sciences (NASDAQ: SAVA) published topline interim-analysis data for simufilam, a potential treatment for Alzheimer's disease. Unfortunately, these developments do not paint a clear path to victory, but instead, they raise more perplexing questions about its science. In the study, the first 50 Alzheimer's patients with mild to moderate disease who received simufilam for a period of 12 months saw their cognition improve by an average of 3.2 points on the Alzheimer's Disease Assessment Cognitive Subscale (ADAS-COG) from baseline.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting